William Blair reaffirmed their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report issued on Friday morning, AnalystRatings.com reports.
A number of other brokerages have also recently commented on ALXN. BidaskClub raised shares of Alexion Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, November 25th. Piper Jaffray Companies set a $180.00 target price on shares of Alexion Pharmaceuticals and gave the company a buy rating in a research report on Friday, September 6th. Morgan Stanley dropped their target price on shares of Alexion Pharmaceuticals from $177.00 to $170.00 and set an overweight rating on the stock in a research report on Friday, October 11th. Robert W. Baird set a $165.00 target price on shares of Alexion Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 30th. Finally, TheStreet cut shares of Alexion Pharmaceuticals from a b- rating to a c+ rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $156.37.
Shares of NASDAQ ALXN opened at $113.89 on Friday. The company has a market capitalization of $25.20 billion, a P/E ratio of 12.45, a price-to-earnings-growth ratio of 0.87 and a beta of 1.67. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $141.86. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.45 and a current ratio of 3.98. The company’s 50 day moving average price is $108.47 and its 200-day moving average price is $112.81.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Resources Management Corp CT ADV bought a new stake in Alexion Pharmaceuticals during the 3rd quarter worth approximately $244,000. Beck Bode LLC boosted its position in shares of Alexion Pharmaceuticals by 7.0% during the third quarter. Beck Bode LLC now owns 25,516 shares of the biopharmaceutical company’s stock valued at $2,499,000 after buying an additional 1,678 shares during the last quarter. Man Group plc grew its holdings in Alexion Pharmaceuticals by 347.3% during the third quarter. Man Group plc now owns 513,104 shares of the biopharmaceutical company’s stock worth $50,254,000 after buying an additional 398,394 shares in the last quarter. Partner Investment Management L.P. bought a new stake in Alexion Pharmaceuticals during the third quarter worth $2,168,000. Finally, Redmile Group LLC bought a new stake in Alexion Pharmaceuticals during the third quarter worth $113,826,000. 91.62% of the stock is owned by institutional investors and hedge funds.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
See Also: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.